Open an account

Balchem

BCPC · NASDAQ

$171.62+$1.20 (+0.70%)TodayMarket closed ·
Prev close $170.42

About BCPC

Balchem Corp. markets specialty performance ingredients and products. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

Employees
1,368
Headquarters
Montvale, Maryland
Listed
Jun 3, 1986
Sector
Materials
Industry
Chemicals
Website
balchem.com

BCPC key statistics

Market cap
5.43B
Price-earnings ratio
33.48
Dividend yield
0.57%
Average volume
241.92K
Volume
336.36K
Open price
$170.68
High today
$172.59
Low today
$169.72
52 Week high
$183.90
52 Week low
$146.21

Balchem (BCPC) at a glance

As of Oct 20, 2026, Balchem (BCPC) shares are priced at $171.62, giving the company a market cap of 5.43B, a price-to-earnings ratio of 33.48 and a dividend yield of 0.57%.

Today the stock has traded between $169.72 and $172.59. The current price is 1.1% above the day's low and 0.6% below its high.

Volume so far is 336.36K shares, above the average of 241.92K shares a day.

Over the past year Balchem has ranged from $146.21 to $183.90, and now sits 67% of the way up that range.

Balchem met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $1.49 per share against an estimate of $1.42.

The average analyst price target is $213.43, 24.4% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 6 analystsAvg $213.43
Low
$166.65
Now
$171.62
High
$254.10

BCPC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 2.0% on average.

  1. Q3 FY24: reported $1.13 per share against an estimate of $1.13
  2. Q4 FY24: reported $1.13 per share against an estimate of $1.13
  3. Q1 FY25: reported $1.22 per share against an estimate of $1.24
  4. Q2 FY25: reported $1.27 per share against an estimate of $1.27
  5. Q3 FY25: reported $1.35 per share against an estimate of $1.34
  6. Q4 FY25: reported $1.31 per share against an estimate of $1.31
  7. Q1 FY26: reported $1.33 per share against an estimate of $1.36
  8. Q2 FY26: reported $1.49 per share against an estimate of $1.42

BCPC news

  • Earnings Outlook For Balchem

  • Balchem's Earnings Outlook

  • Earnings Outlook For Balchem

  • Michael Juliano

    Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time

Similar companies

Companies in the same industry as Balchem

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.